NCT00504426View on ClinicalTrials.gov

Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis

PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

May 31, 2009

Conditions
Pain Due to Osteoporosis
Interventions
DRUG

OPC-249

1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)

Trial Locations (5)

Unknown

Chubu Region

Hokkaido Region

Kanto Region

Kinki Region

Kyushu Region

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY